Josep Bassaganya-Riera, DVM, PhD, founder, Chairman and CEO of Landos Biopharma, delivers a fact-filled overview of his company’s work, developing safer therapeutics for autoimmune disease. Dr. Bassaganya-Riera has received numerous research grants from a wide variety of science and health institutions, including the National Institutes of Health, the United States Department of Agriculture (USDA), as well as many industrial corporations. Dr. Bassaganya-Riera holds the title of Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project, which investigates the various immunoregulatory mechanisms underlying infections with certain gut pathogens by introducing mathematical systems to current mucosal immunology. Dr. Bassaganya-Riera discusses his work with Landos Biopharma, an emerging biotech company that is already an integral player in the development of groundbreaking oral treatments for patients who suffer from autoimmune diseases. He discusses the unmet needs in Crohn's disease treatment in detail, as well as colitis—a chronic digestive disease recognized by inflammation of the colon’s inner lining. Dr. Bassaganya-Riera discusses their successful completion of phase one clinical trials, and he talks about his enthusiasm for further advancement of their therapeutics. The research doctor discusses other diseases of the gastrointestinal tract. He outlines their progress thus far and explains their lead clinical asset, BT-11, which is a unique, oral, locally-acting tiny molecule that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for the treatment of IBD (inflammatory bowel disease). Dr. Bassaganya-Riera has a prolific track record of publishing and securing his important work and has published over 100 scientific papers, and secured 9 patents. He was awarded the 2018 Research Excellence Award from the prestigious Biocomplexity Institute of Virginia Tech.